
Pulmonary & Critical Care fellow @HarvardPulm • Former Fellow @HarvardSleepMed 🫁 💤 🧠 • Respiratory Control, Mechanical Ventillation, NIPPV
- Tweets216
- Following1.2K
- Followers525
- Likes3K

ALT Lessons: The road is bumpy; failure is a step in the process of succeeding. Accept when things are not perfect and don't let that get in the way. The best experiment is the one most likely to disprove the hypothesis. Celebrate when you find you have been wrong about something: it is an opportunity to learn.
![The New England Journal of Medicine Original Article Inhaled Amikacin to Prevent Ventilator-Associated Pneumonia Stephan Ehrmann, M.D., Ph.D., François Barbier, M.D., Ph.D., Julien Demiselle, M.D., [...] for the Reva and CRICS-TRIGGERSEP F-CRIN Research Networks. Strengths: RCT with robust protocol to ensure double-blinding Large and multi-center Powered and enrolled appropriately for primary outcome Good adherence to study protocol, low rates of drop-out/missing data. Limitations: High incidence of VAP across the study - 18.5% overall (22% in placebo arm) VAP definition directly dependent on positive respiratory culture, challenging to definitively diagnose./adjudicate - Bias to primary outcome via clearing of non-infectious culture data No significant difference in any patient-centered (secondary) outcomes - not powered for such analysis, per investigators. Does VAP matter?](https://pbs.twimg.com/media/F-2JYYCb0AANlTD.jpg?name=small&format=webp)
ALT The New England Journal of Medicine Original Article Inhaled Amikacin to Prevent Ventilator-Associated Pneumonia Stephan Ehrmann, M.D., Ph.D., François Barbier, M.D., Ph.D., Julien Demiselle, M.D., [...] for the Reva and CRICS-TRIGGERSEP F-CRIN Research Networks. Strengths: RCT with robust protocol to ensure double-blinding Large and multi-center Powered and enrolled appropriately for primary outcome Good adherence to study protocol, low rates of drop-out/missing data. Limitations: High incidence of VAP across the study - 18.5% overall (22% in placebo arm) VAP definition directly dependent on positive respiratory culture, challenging to definitively diagnose./adjudicate - Bias to primary outcome via clearing of non-infectious culture data No significant difference in any patient-centered (secondary) outcomes - not powered for such analysis, per investigators. Does VAP matter?

ALT The New England Journal of Medicine Original Article Simvastatin in Critically Ill Patients with COVID-19 The REMAP-CAP Investigators Conclusion: Among critically ill patientis with COVID-19, there was a very high probability (96%) that simvastatin improved outcomes. However it did not achieve the pre-specified criteria for superiority. Discussion Points Open label design COVID subtypes (hypo vs hyperinflammatory) - steroids, tocilizumab, vaccination, viral properies. Bayesian designs and response adaptive randomization Next steps

ALT Lessons Learned -Diagnosing pleural TB (tuberculosis) is challenging due to the paucibacillary nature of the infection. -Many challenges exist in ruling-out LTBI (Latent Tuberculosis Infection) in high-prevalence populations and no single pleural fluid study or serologic test is adequate. -PPV/NPV (positive and negative predictive values) of test depend on the prevalence of disease in population of interest. -Pleural ADA (adenosine deaminase) < 40 can rule-out TPE (tuberculous pleural effusion) in LOW prevalence populations. -Pleural ADA > 40 + lymphocytic effusion is highly suggestive of TB in high-prevalence populations.






























